129 related articles for article (PubMed ID: 7798747)
1. [Clinical application of adoptive immunotherapy in patients with progressive lung cancer].
Cho T; Yoshizawa H
Nihon Naika Gakkai Zasshi; 1994 Sep; 83(9):1543-8. PubMed ID: 7798747
[No Abstract] [Full Text] [Related]
2. [Intrapleural administration of LAK cells combined with rIL2 in the treatment of advanced lung cancer with malignant pleural effusion].
Mao G; Gao Z; Wang Q
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):83-4, 127. PubMed ID: 7553956
[TBL] [Abstract][Full Text] [Related]
3. A new approach to the treatment of malignant effusion.
Li DJ; Wang YR; Tan XY; Wang HZ; Yao XD; Ba DN
Chin Med J (Engl); 1990 Dec; 103(12):998-1002. PubMed ID: 2127253
[TBL] [Abstract][Full Text] [Related]
4. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
Liu X
Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):205-8. PubMed ID: 8261867
[TBL] [Abstract][Full Text] [Related]
5. [Postsurgical adjuvant immunotherapy against primary non-small cell lung cancer].
Kimura H; Iwai N; Suzuki M; Takahashi Y
Nihon Geka Gakkai Zasshi; 1998 May; 99(5):279-84. PubMed ID: 9656236
[TBL] [Abstract][Full Text] [Related]
6. Cytokine immunotherapy of non-small cell lung cancer.
Dubinett SM; Kradin RL
Reg Immunol; 1993; 5(3-4):232-43. PubMed ID: 8240940
[No Abstract] [Full Text] [Related]
7. Treatment of 121 patients with malignant effusion due to advanced lung cancer by intrapleural transfer of autologous or allogeneic LAK cells combined with rIL-2.
Liu X; Li D; Zhang C; Ba D; Liu J; Wan T; Li Z; Jin Y; He Y
Chin Med Sci J; 1993 Sep; 8(3):186-9. PubMed ID: 8142637
[TBL] [Abstract][Full Text] [Related]
8. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.
Kimura H; Yamaguchi Y
Cancer; 1997 Jul; 80(1):42-9. PubMed ID: 9210707
[TBL] [Abstract][Full Text] [Related]
9. [Intrapleural transfer of LAK cells combined with rIL-2 in the treatment of advanced lung cancer with malignant pleural effusion].
Li DJ
Zhonghua Zhong Liu Za Zhi; 1989 Jul; 11(4):294-6. PubMed ID: 2625114
[TBL] [Abstract][Full Text] [Related]
10. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
[TBL] [Abstract][Full Text] [Related]
11. [Comparative study of video-assisted thoracoscopic surgery vs thoracic tube drainage in synthetic therapy for malignant pleural effusion secondary to non-small cell lung cancer].
Gu LJ; Wang WJ
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jul; 26(7):1023-6. PubMed ID: 16864104
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with malignant pleural effusions due to advanced lung cancer by transfer of autologous LAK cells combined with rIL-2 or rIL-2 alone.
Li D; Wang Y; Yao X; Shao J; Chen Y; Ba D
Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(1):51-5. PubMed ID: 2371266
[No Abstract] [Full Text] [Related]
13. Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer.
Kimura H; Yamaguchi Y
Lung Cancer; 1995 Aug; 13(1):31-44. PubMed ID: 8528638
[TBL] [Abstract][Full Text] [Related]
14. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
Guo YS; Xing ZL
Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
[TBL] [Abstract][Full Text] [Related]
15. [Combination of adoptive immunotherapy and chemotherapy against advanced cancer with peritoneal dissemination].
Iwahashi M; Tanimura H; Yamaue H; Tsunoda T; Tani M; Tamai M; Taniguchi K; Aoki Y
Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1558-64. PubMed ID: 2172423
[TBL] [Abstract][Full Text] [Related]
16. [Observation of the effects of LAK/IL-2 therapy combining with Lycium barbarum polysaccharides in the treatment of 75 cancer patients].
Cao GW; Yang WG; Du P
Zhonghua Zhong Liu Za Zhi; 1994 Nov; 16(6):428-31. PubMed ID: 7720497
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy for nonsmall cell lung carcinoma. A fourth treatment modality, complicated radiation sensitizer, or none of the above.
Karp DD; Atkins MB
Cancer; 1996 Jul; 78(2):195-8. PubMed ID: 8673991
[No Abstract] [Full Text] [Related]
18. [New aspects of adoptive immunochemotherapy in disseminated forms of cancer].
Normantovich VA; Laktionov KP; Kadagidze ZG; Savel'eva EV; Khlebnov AV; Vysotskaia IV
Vopr Onkol; 1992; 38(6):682-8. PubMed ID: 1338670
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
Wu C; Jiang J; Shi L; Xu N
Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy and operations in the treatment of lung cancer with pleural effusion.
Reyes L; Parvez Z; Regal AM; Takita H
J Thorac Cardiovasc Surg; 1991 May; 101(5):946-7. PubMed ID: 1850812
[No Abstract] [Full Text] [Related]
[Next] [New Search]